Business Model
YM BioSciences Inc. is a life sciences product development company advancing a diverse portfolio of promising hematology and cancer-related products at various stages of development.

CYT387
Novel JAK1/JAK2 inhibitor for multiple indications including myeloproliferative neoplasms (MPNs)

Nimotuzumab
Anti-cancer antibody that targets the epidermal growth factor receptor (EGFR)

CYT997
Novel anti-cancer vascular disrupting agent (VDA)

news

May 11, 2012 YM BioSciences Reports Operational and Financial Results for the Third Quarter of Fiscal 2012

February 29, 2012 YM BioSciences Raises US$80.5 Million from Public Offering

February 24, 2012 YM BioSciences Prices $70 Million Public Offering of Common Shares

View All

events

May 16, 2012 Bank of America Merrill Lynch 2012 Health Care Conference

Brahms III, Encore at the Wynn
Las Vegas, NV

View All

presentations

May 14, 2012 YM BioSciences Corporate Presentation (Calendar Second Quarter 2012)

view presentation (PDF 556 KB)

View All

videos

CYT387

nimotuzumab

CYT997

reports

View All

Second Quarter Results (PDF 680 KB)

First Quarter Results (PDF 564 KB)

Annual Report 2011 (PDF 636 KB)

posters & publications

Safety and Efficacy of CYT387, a JAK1 and JAK2 Inhibitor for the Treatment of Myelofibrosis. Pardanani, et al. 2011 American Society of Hematology (ASH) Annual Meeting